Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Ingresos totales | ₹167.1B | ₹131.5B | ₹116.4B | ₹114.3B | — |
| Beneficio bruto | ₹116.0B | ₹83.9B | ₹67.6B | ₹68.5B | — |
| Ingresos operativos (EBIT) | ₹40.2B | ₹18.7B | ₹6.3B | ₹10.8B | — |
| Ingresos netos | ₹13.6B | ₹10.5B | (₹15.0B) | ₹3.0B | — |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de GLENMARK. /companies/us/GLENMARK
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms